Loading…
Candel Therapeutics, Inc. is projected to rise to $13.22 by 2027, a +32% move from its current price of $10.01. CADL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $9.71 | $10.02 | $10.34 | +0.10% |
| Aug 3 | $9.59 | $10.03 | $10.49 | +0.19% |
| Aug 4 | $9.50 | $10.04 | $10.60 | +0.29% |
| Aug 5 | $9.43 | $10.05 | $10.70 | +0.39% |
| Aug 6 | $9.37 | $10.06 | $10.80 | +0.48% |
| Aug 7 | $9.32 | $10.07 | $10.88 | +0.58% |
| Aug 8 | $9.27 | $10.08 | $10.96 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.27 | $10.08 | $10.96 | +0.68% |
| Week 2 | $9.01 | $10.15 | $11.42 | +1.36% |
| Week 3 | $8.84 | $10.21 | $11.81 | +2.05% |
| Week 4 | $8.70 | $10.28 | $12.16 | +2.74% |
| Week 5 | $8.59 | $10.35 | $12.48 | +3.43% |
| Week 6 | $8.49 | $10.42 | $12.79 | +4.14% |
| Week 7 | $8.41 | $10.49 | $13.09 | +4.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer, and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
CADL is currently priced at $9.40 per share. It has a market capitalization of $688.74M and a market rank of 2788.
Forecasts show a near-term baseline in 2026 with min $4.48, avg $9.40, max $13.24 and ROI 0; sentiment NEUTRAL. From 2027 onward, upside grows, with 2027 avg $12.48 (ROI 32.8%), 2028 avg $14.41 (ROI 53.3%), 2029 avg $16.68 (ROI 77.5%), and 2030 avg $22.69 (ROI 141.4%).
By 2040 the forecast shows avg $80.76, min $48.44, max $143.54 with ROI 759.1 and sentiment BULLISH, and by 2050 avg $169.08, min $87.67, max $331.99 with ROI 1698.8 and sentiment BULLISH.
A major floor 55.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.0% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 16.0% above — clearing it would confirm fresh momentum.
Key CADL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CADL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.78 | Buy | $9.83 | Buy |
| MA 10 | $9.82 | Buy | $9.80 | Buy |
| MA 20 | $9.81 | Buy | $9.72 | Buy |
| MA 50 | $9.16 | Buy | $9.10 | Buy |
| MA 100 | $7.63 | Buy | $8.15 | Buy |
| MA 200 | $6.54 | Buy | $7.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.24 | Neutral |
| Stoch RSI (14) | 51.56 | Neutral |
| CCI (20) | 66.90 | Neutral |
| Williams %R (14) | -25.61 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 3.84 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 74.39 | Neutral |
| TRIX (15) | 0.36 | Buy |
| Awesome (5,34) | 0.23 | Buy |
| Ultimate (7,14,28) | 50.81 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 9.71 | Buy |
| ADX (14) | 14.49 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day technical picture shows a bullish tilt with RSI14 at 50, suggesting balanced momentum near the midline. The SMA50 sits at $9.07 and the SMA200 at $6.50, providing near-term trend references. Support is identified at $7.97 and resistance at $10.36, with a 30-day price range of $7.62 to $11.60.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.48 | $10.01 | $14.00 | 0% | Neutral | |
| $10.39 | $13.22 | $17.87 | +32% | Bullish | |
| $11.56 | $15.20 | $21.44 | +52% | Bullish | |
| $12.96 | $17.53 | $25.55 | +75% | Bullish | |
| $17.31 | $23.98 | $35.94 | +140% | Bullish | |
| $20.58 | $29.14 | $44.74 | +191% | Bullish | |
| $23.51 | $34.00 | $53.32 | +240% | Bullish | |
| $28.01 | $41.32 | $66.05 | +313% | Bullish | |
| $27.38 | $41.14 | $66.95 | +311% | Bullish | |
| $28.77 | $44.01 | $72.82 | +340% | Bullish | |
| $49.97 | $82.95 | $146.97 | +729% | Bullish | |
| $90.26 | $173.01 | $338.42 | +16.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.48 | $10.01 | $12.20 | +0.00% |
| September 2026 | $8.97 | $10.67 | $13.07 | +6.57% |
| October 2026 | $9.12 | $10.93 | $13.56 | +2.46% |
| November 2026 | $8.96 | $10.81 | $13.54 | -1.11% |
| December 2026 | $9.13 | $11.08 | $14.00 | +2.46% |
Click any year to see its month-by-month CADL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CADL is projected to trade between $4.48 and $14.00, averaging $10.01 — a potential gain of 0% from today's $10.01. A consolidation phase looks the most probable path here.
Candel Therapeutics, Inc.'s 2027 outlook centres on $13.22, within a $10.39 to $17.87 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2028, CADL could reach as high as $21.44, with a base case around $15.20 and support toward $11.56 — roughly +52% from $10.01. Buyers look set to stay in control over this stretch.
Expect CADL to range from $12.96 to $25.55 through 2029. The $17.53 average target implies a +75% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The CADL price prediction for 2030 points to an average of $23.98 (low $17.31, high $35.94) — a potential gain of +140% on today's $10.01. Buyers look set to stay in control over this stretch.
In 2031, CADL is projected to trade between $20.58 and $44.74, averaging $29.14 — a potential gain of +191% from today's $10.01. That is up +22% on the projected 2030 average. Momentum favours further upside here.
Candel Therapeutics, Inc.'s 2032 outlook centres on $34.00, within a $23.51 to $53.32 range. That is up +17% on the projected 2031 average. That marks a +240% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CADL could reach as high as $66.05, with a base case around $41.32 and support toward $28.01 — roughly +313% from $10.01. Momentum favours further upside here.
Expect CADL to range from $27.38 to $66.95 through 2034. The $41.14 average target implies a +311% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The CADL price prediction for 2035 points to an average of $44.01 (low $28.77, high $72.82) — a potential gain of +340% on today's $10.01. Momentum favours further upside here.
In 2040, CADL is projected to trade between $49.97 and $146.97, averaging $82.95 — a potential gain of +729% from today's $10.01. That is up +88% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Candel Therapeutics, Inc.'s 2050 outlook centres on $173.01, within a $90.26 to $338.42 range. That is up +109% on the projected 2040 average. That marks a +16.3x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CADL today (≈ 99.9001 CADL) could be worth
$17,283.8
+$16,283.8 (+1628%) by 2050 · US Dollar
Based on the average projected CADL price of $173.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CADLwould be worth at today's price.
$1,000 invested in CADL on Jul 31, 2025 (≈ 155.159034 CADL) would be worth
$1,553.14
+$553.14 (+55.3%) today · 1.55× · US Dollar
Based on a CADL entry price of $6.45 vs. today's $10.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.56 | $1,047.07 | +4.7% |
| 1 month ago | $9.88 | $1,013.16 | +1.3% |
| 3 months ago | $6.47 | $1,547.14 | +54.7% |
| 6 months ago | $5.87 | $1,705.28 | +70.5% |
| 1 year ago | $6.45 | $1,553.14 | +55.3% |
| All time (5.0y) ago | $7.5 | $1,334.67 | +33.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CADL forecast.
Our base-case forecast reaches $20.00 around 2030.
Implied market cap at $20.00: $1.47B
The multi-year outlook remains bullish, with 2026 showing a base forecast of min $4.48, avg $9.40, max $13.24 and ROI 0. From 2027 onward, the model projects rising averages: 2027 avg $12.48 (ROI 32.8), 2028 avg $14.41 (ROI 53.3), 2029 avg $16.68 (ROI 77.5), and 2030 avg $22.69 (ROI 141.4).
Looking further out, 2040 foresees avg $80.76 (min $48.44, max $143.54) with ROI 759.1 and bullish sentiment, while 2050 projects avg $169.08 (min $87.67, max $331.99) with ROI 1698.8 and bullish sentiment. These are estimates and not guarantees; actual results will vary with market conditions.
Tap a question to reveal the answer.
Avg $22.69, min $16.35, max $34.08, ROI 141.4, sentiment bullish.
Forecasts show bullish sentiment from 2027 onward with rising averages (2027 avg $12.48, 2028 avg $14.41, 2029 avg $16.68, 2030 avg $22.69) and higher ROI up to 141.4 in 2030, but these are estimates.
Yes, the 2040 max forecast is $143.54, with ROI 759.1 and sentiment bullish; the 2040 average is $80.76.
Current price $9.40; market cap $688.74M.
Sentiment is BULLISH; RSI14 is 50; SMA50 is $9.07; SMA200 is $6.50; support is $7.97 and resistance is $10.36; the 30-day range is $7.62 to $11.60.
Candel Therapeutics, Inc. Community Discussion
0Share your Candel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.